143 related articles for article (PubMed ID: 32207938)
1. (
Duan X; Liu F; Kwon H; Byun Y; Minn I; Cai X; Zhang J; Pomper MG; Yang Z; Xi Z; Yang X
J Med Chem; 2020 Apr; 63(7):3563-3576. PubMed ID: 32207938
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of succinimidyl-Cys-C(O)-Glu derivatives with different near-infrared fluorophores as optical imaging probes for prostate-specific membrane antigen.
Matsuoka D; Watanabe H; Shimizu Y; Kimura H; Yagi Y; Kawai R; Ono M; Saji H
Bioorg Med Chem; 2018 May; 26(9):2291-2301. PubMed ID: 29580851
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of a novel
Sui Y; Duan X; Zhang J; Chu Y; Yang X
Bioorg Med Chem Lett; 2023 Jul; 91():129382. PubMed ID: 37348571
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine-based asymmetric urea ligand for prostate carcinoma: Tuning biological efficacy through in silico studies.
Sengupta S; Krishnan MA; Pandit A; Dudhe P; Sharma R; Chelvam V
Bioorg Chem; 2019 Oct; 91():103154. PubMed ID: 31404798
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Son SH; Kwon H; Ahn HH; Nam H; Kim K; Nam S; Choi D; Ha H; Minn I; Byun Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126894. PubMed ID: 31874825
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of a novel urea-based
Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
[TBL] [Abstract][Full Text] [Related]
9. Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer.
Wang X; Chen Y; Xiong Y; Zhang L; Wang B; Liu Y; Cui M
J Med Chem; 2023 May; 66(10):6889-6904. PubMed ID: 37161996
[TBL] [Abstract][Full Text] [Related]
10. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
11. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging.
Harada N; Kimura H; Ono M; Saji H
J Med Chem; 2013 Oct; 56(20):7890-901. PubMed ID: 24063417
[TBL] [Abstract][Full Text] [Related]
12. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
13. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Hillier SM; Kern AM; Maresca KP; Marquis JC; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2011 Jul; 52(7):1087-93. PubMed ID: 21680691
[TBL] [Abstract][Full Text] [Related]
14. Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
Bakht MK; Hayward JJ; Shahbazi-Raz F; Skubal M; Tamura R; Stringer KF; Meister D; Venkadakrishnan VB; Xue H; Pillon A; Stover M; Tronchin A; Fifield BA; Mader L; Ku SY; Cheon GJ; Kang KW; Wang Y; Dong X; Beltran H; Grimm J; Porter LA; Trant JF
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35064078
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer.
Kwon YD; Oh JM; La MT; Chung HJ; Lee SJ; Chun S; Lee SH; Jeong BH; Kim HK
Bioconjug Chem; 2019 Jan; 30(1):90-100. PubMed ID: 30485073
[TBL] [Abstract][Full Text] [Related]
16. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
[TBL] [Abstract][Full Text] [Related]
17. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
19. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
20. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
